Ansell Limited’s stock plummeted despite reporting decent performance in FY 18

Ansell Limited’s stock plummeted despite

Decent FY 18 Performance: Ansell Limited’s (ASX: ANN) stock plummeted 8.2% on August 20, 2018 after the company reported FY18 Statutory Profit Attributable of $484m, that includes $345m after-tax gain on sale of Sexual Wellness and 8% rise in sales from continuing operations $1,490m on a year on year (yoy) basis. Further, for FY 18, adjusted EBIT increased 9% to $193m YOY. The company has increased full year dividend to US45.5¢ and final dividend is up 5% to US25.0¢. Additionally, for FY 19, ANN expects external market conditions to generally remain supportive to top line growth.

However, they are also creating tight demand / supply conditions especially for nitrile latex and this led to rise in the raw material costs for these and other materials, with only limited offset from a weaker natural rubber latex price. Further, the impact of the potential introduction of new tariffs on imports from the US to China is uncertain. For 2019, the organic revenue growth is expected in the 3-5% range, and the group expects transformation cost benefits, pricing and product mix actions to benefit EBIT growth. FY19 EPS is expected to be  approx. 3-5¢ vs FY18 and the adjusted EPS is expected to be in the range $1.00 to $1.12. Meanwhile ANN stock has risen 4.35% in three months as on August 17, 2018  and is trading at a P/E of 6.27x.

ANN Repport

FY 18 Financial Performance (Source: Company Reports)

Dividend Stocks To Buy

The Income available from dividends remains attractive for many investors.

We take a look at the best yields on the market and assess what they say about a company’s prospect.

One Thing is certain, though, Australia interest rates are still low, making income difficult to come by and keeping the focus for many investors on high yielding stocks. Kalkine’s team of analysts bought you handpicked report for “Top 25 Dividend Stocks For 2018.”

ASX-relevant Special Reports are published year-round to provide a detailed analysis into an investing opportunity or a potential risk to your portfolio.

Click here to get your free report.


The advice given by Kalkine Pty Ltd and provided on this website is general information only and it does not take into account your investment objectives, financial situation or needs. You should therefore consider whether the advice is appropriate to your investment objectives, financial situation and needs before acting upon it. You should seek advice from a financial adviser, stockbroker or other professional (including taxation and legal advice) as necessary before acting on any advice. Not all investments are appropriate for all people. and associated websites are published by Kalkine Pty Ltd ABN 34 154 808 312 (Australian Financial Services License Number 425376). website), employees and/or associates of Kalkine Pty Ltd do not hold positions in any of the stocks covered on the website. These stocks can change any time and readers of the reports should not consider these stocks as advice or recommendations.

Join Our Discussion

Start discussion with value Investors for ASX Stock Market Investment and Opinion.

6 Cannabis Stocks under Investor’s Limelight…

Cannabis companies that sell both medicinal weed and recreational pot. Marijuana stocks to look at. Marijuana mergers and acquisitions. Dispensary data analytics. Upcoming marijuana IPO’s Those phrases have become increasingly common as marijuana legalization spreads.

Global spending on legal cannabis is expected to grow 230% to $32 billion in 2020 as compared to $9.5 in 2017, according to Arcview Market Research and BDS Analytics. As of June 29, 2018 the United States Marijuana Index, despite a lot of uncertainty around regulations, has over the past 1 year gained 71.49%, as compared to about 12% gain seen by the S&P 500.

Click here for your FREE Report